1. Home
  2. TRX vs CTMX Comparison

TRX vs CTMX Comparison

Compare TRX & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TRX Gold Corporation

TRX

TRX Gold Corporation

HOLD

Current Price

$0.90

Market Cap

228.9M

Sector

N/A

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$4.12

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRX
CTMX
Founded
1990
2008
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
228.9M
596.2M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
TRX
CTMX
Price
$0.90
$4.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$1.25
$6.50
AVG Volume (30 Days)
1.4M
2.1M
Earning Date
01-13-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.22
EPS
0.00
0.24
Revenue
$57,613,000.00
$113,631,000.00
Revenue This Year
$28.16
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$363.98
$17.49
Revenue Growth
39.98
N/A
52 Week Low
$0.27
$0.40
52 Week High
$0.89
$4.62

Technical Indicators

Market Signals
Indicator
TRX
CTMX
Relative Strength Index (RSI) 72.25 56.75
Support Level $0.82 $3.78
Resistance Level $0.89 $4.20
Average True Range (ATR) 0.05 0.23
MACD 0.02 -0.01
Stochastic Oscillator 98.21 72.39

Price Performance

Historical Comparison
TRX
CTMX

About TRX TRX Gold Corporation

TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: